Clinical Trial Update: Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating genetically engineered natural killer (NK) cells with or without atezolizumab for non-small cell lung cancer in patients pre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Genetically engineered natural killer (NK) cells

Snippet

Sponsor: University of California, Irvine | Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING